Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Raw Materials (2017 - 2024)

China Pharma Holdings (CPHI) has disclosed Raw Materials for 8 consecutive years, with $869820.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Raw Materials fell 53.69% year-over-year to $869820.0, compared with a TTM value of $869820.0 through Sep 2024, down 53.69%, and an annual FY2023 reading of $1.8 million, up 0.52% over the prior year.
  • Raw Materials was $869820.0 for Q3 2024 at China Pharma Holdings, down from $1.2 million in the prior quarter.
  • Across five years, Raw Materials topped out at $2.2 million in Q1 2023 and bottomed at $869820.0 in Q3 2024.
  • Average Raw Materials over 5 years is $1.8 million, with a median of $1.8 million recorded in 2021.
  • The sharpest move saw Raw Materials rose 20.5% in 2023, then plummeted 53.69% in 2024.
  • Year by year, Raw Materials stood at $2.1 million in 2020, then fell by 11.63% to $1.8 million in 2021, then changed by 0.0% to $1.8 million in 2022, then rose by 0.52% to $1.8 million in 2023, then crashed by 52.96% to $869820.0 in 2024.
  • Business Quant data shows Raw Materials for CPHI at $869820.0 in Q3 2024, $1.2 million in Q2 2024, and $1.7 million in Q1 2024.